[Cytotoxicity of lymphokine-activated killer cells in conjunction with pingyangmycin to human tongue carcinoma (Tca8113) in vitro and vivo].
Duan
J G
JG
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use* / Q000031:analogs & derivatives; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D014062:Tongue Neoplasms / Q000473:pathology / Q000628:therapy*; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; C021771:zhengguangmycin